InvestorsHub Logo
Followers 67
Posts 12931
Boards Moderated 0
Alias Born 06/03/2015

Re: attilathehunt post# 134316

Thursday, 12/14/2017 11:57:38 AM

Thursday, December 14, 2017 11:57:38 AM

Post# of 469767
I don't believe Missling has a deceitful bone in his body. I believe he truly was planning/hoping to start trials as stated. Likely underestimated the amount of red tape associated with the FDA. Apparently Fadiran was not able to expedite processes has hoped. To me, this doesn't minimize all of the positive developments that have happened and continue to unfold. The timing will always be uncertain, because of 3rd-part involvement, especially the FDA.

His scheduled share purchases from the beginning of last fall were likely just a signal that all is well, in general, and that CTAD data will be positive. Check and check!

Perhaps the PD trial plans were modified (?), realizing available resources, funding and professional involvement already in place in Sweden (?). But the point is, it's progressing and will eventually produce favorable results. It's the Rett trial that will set the pace for 2018.

There is a lot going on with this company (three trials for prominent indications), with better than 50% chance of success (IMO). Don't know of any other small biotech startup that has such a position.

Staying long...

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AVXL News